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Combination therapy of tiotropium and
ciclesonide attenuates airway inflammation
and remodeling in a guinea pig model of
chronic asthma
Loes E. M. Kistemaker1,2*, I. Sophie T. Bos1,2, Mark H. Menzen1,2, Harm Maarsingh3, Herman Meurs1,2
and Reinoud Gosens1,2
Abstract
Background: The long-acting anticholinergic tiotropium has recently been registered for the treatment of asthma,
and its use is associated with a reduction in exacerbation frequency. Anti-inflammatory and anti-remodeling effects
of tiotropium have been demonstrated in in vitro and in vivo models. Because tiotropium treatment is used in
combination with inhaled corticosteroids, potential additive effects between the two would be clinically relevant.
Therefore, the aim of this study was to investigate additive effects between tiotropium and ciclesonide on airway
inflammation and remodeling in guinea pig models of asthma.
Methods: Guinea pigs (n = 3–8/group) were sensitized and challenged with ovalbumin in an acute (single
challenge) and a chronic model (12 weekly challenges) of allergic asthma. Animals were treated with vehicle,
nebulized tiotropium (0.01–0.3 mM) and/or intranasally instilled ciclesonide (0.001–1 mg/kg) before each challenge.
Bronchoalveolar lavage fluid and lungs were collected for analysis of airway inflammation and remodeling.
Results: Tiotropium and ciclesonide treatment, alone or in combination, did not inhibit airway inflammation in the
acute asthma model. In a dose-finding study, low doses of tiotropium and ciclesonide inhibited airway eosinophilia
and airway smooth muscle thickening in the chronic asthma model. Threshold doses of 0.01 mM tiotropium
(nebulizer concentration) and 0.01 mg/kg ciclesonide were selected to investigate potential additive effects
between both drugs. At these doses, tiotropium and ciclesonide did not inhibit airway eosinophilia or airway
smooth muscle thickening when administered alone, but significantly inhibited these allergen-induced responses
when administered in combination.
Conclusions: Combined treatment with low doses of tiotropium and ciclesonide inhibits airway inflammation and
remodeling in a guinea pig model of chronic asthma, suggesting that combined treatment with anticholinergics
and corticosteroids may have anti-inflammatory and anti-remodeling activity in allergic airway diseases. Since
tiotropium is registered as a therapy for asthma added on to corticosteroid treatment, these beneficial effects of
the combination therapy may be clinically relevant.
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Background
Asthma is a common obstructive airway disease, which
currently affects around 300 million people worldwide
and has a major debilitating impact on society [1]. In
most cases, asthma is associated with an allergic re-
sponse towards inhaled aeroallergens. Patients with
asthma suffer from inflammation of the airways, causing
hyperresponsiveness to specific and non-specific stimuli.
This inflammation is characterized by an increase in eo-
sinophils, CD4+ lymphocytes and TH2 cytokines includ-
ing IL-4, IL-5 and IL-13 [2]. Moreover, remodeling of
the bronchial tree is a significant pathology in severe
asthma that contributes to airflow obstruction and loss
of deep breath-induced bronchodilation [3]. Remodeling
of the airways is characterized by increased extracellular
matrix deposition in the subepithelial airway compart-
ment and marked thickening of the bronchial smooth
muscle. All these changes are associated with airflow
limitation in severe asthma [4].
Current treatment for patients with asthma includes
inhaled corticosteroids (ICS) and long-acting β2-agonists
(LABA). Moreover, the long-acting muscarinic antagon-
ist (LAMA) tiotropium has recently been registered for
the treatment of asthma. Clinical trials have shown bene-
ficial effects on lung function by addition of tiotropium to
standard treatment in moderate and severe asthma pa-
tients [5–7]. In addition, treatment with tiotropium re-
duced the number of severe exacerbations [5], suggesting
that tiotropium might exert anti-inflammatory effects in
these patients.
Anti-inflammatory effects of anticholinergics have in-
deed been observed in in vitro and in vivo studies using
various experimental models [8, 9]. In vitro, anticholin-
ergics exert direct anti-inflammatory effects on inflam-
matory cells, including T cells [10] and macrophages
[11], on epithelial cells [12], and on airway smooth
muscle cells [13]. In addition, anticholinergics affect air-
way remodelling in vitro [9]. Muscarinic receptors regu-
late proliferation of airway smooth muscle cells [14] and
fibroblasts [15], fibroblast to myofibroblast transition
[16], and extracellular matrix deposition [17, 18]. These
findings have been confirmed in in vivo animal models,
demonstrating inhibitory effects of tiotropium or mus-
carinic M3 receptor knock-out on ovalbumin-induced
inflammation and remodeling, including airway smooth
muscle thickening, extracellular matrix deposition and
mucus gland hypertrophy [19–22]. Effects of tiotropium
on ovalbumin-induced inflammation and remodeling
were comparable to the effects of the corticosteroid
budesonide [22]. The effects of the combination of tio-
tropium and a corticosteroid on airway inflammation
and remodeling are currently unknown. In vitro, it has
been shown that the anticholinergic glycopyrrolate acts
synergistically with budesonide in inhibiting TNF-α
release from isolated monocytes [23], suggesting that the
combination of anticholinergics and corticosteroids
might be more effective than the monotherapies in vivo.
In view of the above mentioned beneficial effects of
tiotropium and corticosteroids on allergic airway inflam-
mation and remodeling, combination therapy with anti-
cholinergics and corticosteroids might have additive
protective effects on airway inflammation and remodel-
ing. Therefore, in the present study, the effects of pre-
treatment with tiotropium and ciclesonide on airway
inflammation and remodeling were investigated using
guinea pig models of acute and chronic asthma. Guinea
pig models are valuable for the evaluation of patho-
physiological mechanisms and pharmacological inter-
ventions in asthma, since the mechanisms underlying
the allergic asthmatic reaction in guinea pigs are more
comparable to humans, and therefore more physiologic-
ally relevant compared to commonly used rodent models
[24]. In these guinea pig models, we demonstrate that
tiotropium and ciclesonide do not inhibit acute
allergen-induced inflammation, but do inhibit chronic
allergen-induced airway inflammation and remodeling
when applied in combination.
Methods
Animals
Outbred male, specified pathogen-free Dunkin Hartley
guinea pigs (Harlan, Heathfield, UK), weighing 500–800 g,
were used in this study. The animals were group-housed
in individual cages in climate-controlled animal quarters
and given water and food ad libitum, while a 12-h on/12-h
off light cycle was maintained. All protocols described
were approved by the University of Groningen Committee
for Animal Experimentation (DEC6081).
Ovalbumin administration
The animals were actively IgE-sensitized to ovalbumin
as described previously [22]. In short, 0.5 ml of an aller-
gen solution containing 100 μg/ml ovalbumin and
100 mg/ml Al(OH)3 in saline was injected intraperitone-
ally, while another 0.5 ml was divided over seven intracu-
taneous injection sites in the proximity of lymph nodes in
the paws, lumbar regions, and the neck. The animals were
used experimentally 5 weeks after sensitization (Fig. 1).
Challenges with ovalbumin (0.05–0.1 % in saline; Sigma
Chemical, St. Louis, MO) were performed by inhalation of
aerosolized solutions until airway obstruction, as de-
scribed previously [22]. The average ovalbumin dose to
induce airway obstruction at the end of the protocol in
the control group was 909 ± 1221 μg. The dose needed in
the tiotropium and ciclesonide group was not different
(302 ± 140 and 409 ± 259 μg respectively), whereas the
dose was slightly higher in the group treated with the com-
bination of tiotropium and ciclesonide (1759 ± 1326 μg).
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These differences in ovalbumin dose between the different
groups were not statistically significant. Aerosols were
produced by a DeVilbiss nebulizer (type 646; DeVilbiss,
Somerset, PA) driven by an airflow of 8 l/min and resulting
in an output of 0.33 ml/min. Provocations were carried out
in a perspex cage (internal volume of 9 l) in which the
guinea pigs could move freely.
Drug administration
Tiotropium treatment (nebulizer concentration 0.01–
0.3 mM in saline; Boehringer Ingelheim Pharma GmbH)
was administered via inhalation of aerosolized solutions
for 3 min, as described above for ovalbumin challenges.
Treatment was performed 1 h prior to each ovalbumin
challenge. Ciclesonide treatment was not possible via
nebulization because of the poor solubility, and was
therefore administered via intranasal instillation (0.001–
1 mg/kg in saline containing 0.2 % Tween 80; Bufa BV).
Conscious guinea pigs were held in an upright position,
while 200 μl ciclesonide was slowly instilled intranasally.
After the instilled solution was aspirated, the animals
were kept in the upright position for an additional 2 min
to allow sufficient spreading of the fluid throughout the
airways. Ciclesonide treatment was performed 24 h and
1 h prior to each ovalbumin challenge. Control animals
were instilled with 200 μl sterile saline containing 0.2 %
Tween 80.
Acute asthma model
In the acute protocol, all animals were sensitized to ov-
albumin as described above, and received a single saline
or ovalbumin challenge 5 weeks after sensitisation (Fig. 1a).
Animals were treated with different dosages of tiotropium
(0.01, 0.03, 0.1 and 0.3 mM, 3 min inhalation time), cicle-
sonide (0.001, 0.01, 0.1 and 1 mg/kg) or the combination
of tiotropium and ciclesonide (0.1 mM and 1 mg/kg, re-
spectively) before ovalbumin challenge (Additional file 1:
Table S1). Twenty five hours after the ovalbumin chal-
lenge, animals were anaesthetized with 20 mg/ml Brietal-
sodium, 35 mg/kg ketamine hydrochloride and 6 mg/kg
Sedamun intraperitoneally, which ensured a fast, deep
anaesthesia. The lungs were gently lavaged with 5 ml of
sterile saline at 37 °C using a tracheal cannula, followed by
three subsequent aliquots of 8 ml of saline. The recovered
samples were placed on ice and centrifuged at 290 g for
10 min at 4 °C. The combined pellets were resuspended to
a final volume of 1.0 ml in PBS, and total cell numbers
were counted using a coulter counter (Casy Rock). For
Fig. 1 Experimental procedure. a acute protocol, b chronic protocol. Male Dunkin Hartley guinea pigs (n = 3–8 animals per group, see Additional
file 1: Table S1-S3 for overview of groups) were sensitized to ovalbumin (OVA) by intraperitoneal injection of 0.5 ml allergen solution containing
100 μg/ml ovalbumin and 100 mg/ml Al(OH)3, and intracutaneous injection of 0.5 ml allergen solution. Subsequently, guinea pigs were challenged
with OVA (0.05–0.1 %) via inhalation of aerosolized solution. Tiotropium (tio; 0.01–0.3 mM; 3 min inhalation time) was administered via
aerosol inhalation and ciclesonide (cicl; 0.001–1 mg/kg) via intranasal instillation, 24 h and/or 1 h before every challenge. In the acute
protocol, a bronchoalveolar lavage was performed 25 h after the ovalbumin challenge. In the chronic protocol, lungs were harvested for
tissue sections 24 h after the last of 12 weekly OVA challenges
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cytological examination, cytospin preparations were
stained with May-Grünwald and Giemsa stain (Sigma
Chemical, St. Louis). A cell differentiation was performed
by counting at least 400 cells in duplicate.
Chronic asthma model
In the chronic protocol, all animals were sensitized to
ovalbumin as described above, and 5 weeks later re-
ceived saline or ovalbumin challenges once weekly for
12 weeks (Fig. 1b). Animals were treated with different
dosages of tiotropium and/or ciclesonide prior to each
challenge. In the first chronic dose-finding study, tio-
tropium nebulizer doses of 0.01 mM and 0.03 mM
(3 min inhalation time) and ciclesonide doses of
0.01 mg/kg and 0.1 mg/kg were tested. See Additional
file 1: Table S2 for an overview of the experimental
groups included (6 groups, 4 animals per group). Based
on these results, 0.01 mM tiotropium and 0.01 mg/kg
ciclesonide were selected for follow-up studies investigat-
ing interactions between both drugs. See Additional file 1:
Table S3 for an overview of the experimental groups in-
cluded in this study (6 groups, 8 animals per group).
Twenty-four hours after the last challenge, guinea pigs
were sacrificed by experimental concussion, followed by
rapid exsanguination. Lungs were inflated with a fixed
amount (6 mL) of saline:tissue tek solution, which was
gently instilled into the lungs. The lungs were immediately
resected and kept on ice for further processing. Transverse
frozen cross-sections of the main bronchi in the right lung
lobes were used for histological and immunohistochemical
analyses as described previously [22]. To optimally pre-
serve the lungs for these histological analyses, no bron-
choalveolar lavage was performed prior to the lung
resection in this chronic study. To identify eosinophils,
sections were stained with haematoxylin and eosin (Sigma
Chemical, St. Louis). To identify smooth muscle, sections
were stained for smooth muscle-myosin heavy chain (sm-
MHC; Neomarkers; Fremont, CA, USA) and visualised
using an HRP-linked secondary antibody, diaminobenzi-
dine (0.3 mg/ml). Negative control staining without pri-
mary antibody was performed to demonstrate specificity.
To identify collagen fibers, sections were stained with a
Sirius Red stain. Airways within sections were digitally
photographed and classified as cartilaginous or non-
cartilaginous. The average diameter of the cartilaginous
airways was 2654.6 ± 1275.8 μm and the average diameter
of the non-cartilaginous airways was 548.0 μm±
212.6 μm. All immunohistochemical measurements were
carried out digitally by planimetry using quantification
software (ImageJ). For this purpose, the digital photo-
graphs were blinded and analysed at a magnification of
40-400x. Of each animal, 2 to 4 lung sections were pre-
pared per staining, in which a total of 2 to 6 airways of
each classification were analysed. To quantify eosinophilia,
the number of eosinophils in the different compartments
was counted and expressed relative to basement mem-
brane length. For quantification of smooth muscle mass,
smooth muscle-myosin positive area in the airway wall
compartment was quantified and expressed relative to
square of the basement membrane length.
Statistical analysis
Data are presented as mean ± s.e. of the mean. Statistical
differences between means were calculated using one-
way ANOVA, followed by Holm-Sidak post hoc test
versus ovalbumin-challenged saline-treated animals. Dif-
ferences were considered significant at p < 0.05.
Results
Acute asthma model - inflammation
Ovalbumin challenge induced a 3-fold increase in in-
flammatory cell number in the broncho-alveolar lavage
fluid (BALF) (Fig. 2a), consisting mostly of eosinophils
(Fig. 2b). In addition, there was a small but not signifi-
cant increase in macrophages (Fig. 2c), lymphocytes
(Fig. 2d) and neutrophils (Fig. 2e). Treatment with
tiotropium (0.1 mM; the dose used in previous studies
[21, 22]) had no significant effect on allergen-induced in-
creases in total cell number, eosinophils, macrophages,
neutrophils or lymphocytes (Fig. 2). Ciclesonide treatment
(1 mg/kg) also had no significant effect on inflammatory
cell numbers in the BALF (Fig. 2). The combination of tio-
tropium and ciclesonide was not more effective than the
monotherapies and no significant anti-inflammatory ef-
fects were observed in this acute asthma model, although
the number of lymphocytes was repressed to the level ob-
served in saline-challenged animals by the combination of
tiotropium and ciclesonide (Fig. 2d). The same is true for
the other doses of tiotropium (0.01–0.3 mM) and cicleso-
nide (0.001–0.1 mg/kg) assessed as part of this initial
study (data not shown).
Dose-finding in chronic asthma model - inflammation
As we have previously demonstrated profound anti-
inflammatory effects of tiotropium (0.1 mM) and bude-
sonide (0.1 mM) in a guinea pig model of chronic
asthma [22], we concluded that the acute model is not
predictive for the chronic situation. Therefore, an add-
itional dose-finding study was planned in which the
effects of low to moderate doses of tiotropium (0.01 and
0.03 mM) and ciclesonide (0.01 and 0.1 mg/kg) were
evaluated in a model of chronic asthma in order to se-
lect doses that cause submaximal effects. In contrast to
the findings in the acute model, both tiotropium and
ciclesonide exerted anti-inflammatory effects in the
chronic allergen model. Ovalbumin challenge induced
an increase in the number of eosinophils in the sub-
mucosa (8.4-fold, Fig. 3a) and adventitia (7.0-fold, Fig. 3b)
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Fig. 2 Inflammatory cell numbers in bronchoalveolar lavage fluid in response to a single ovalbumin (OVA) challenge and treatment with saline
(sal; control), tiotropium (tio; 0.1 mM; nebulizer concentration), and/or ciclesonide (cicl; 1 mg/kg). Guinea pigs were treated as described in Fig. 1a.
A bronchoalveolar lavage was performed 25 h after OVA challenge and inflammatory cells were determined. a total cells, b eosinophils, c macrophages,
d lymphocytes, e neutrophils. ** p < 0.01, *** p < 0.001. Data represent mean ± s.e.m. of 5–8 animals per group
Fig. 3 Airway eosinophilia in response to chronic ovalbumin (OVA) challenge and treatment with saline (sal; control), tiotropium (tio; 0.01 and
0.03 mM; nebulizer concencenrations) or ciclesonide (cicl; 0.01 and 0.1 mg/kg). Guinea pigs were treated as described in Fig. 1b. Lungs were collected
24 h after the last OVA challenge and eosinophil numbers were determined by H&E staining in the submucosa (a,c) and adventitia (b,d) of the
non-cartilaginous (a,b) and cartilaginous airways (c,d). * p < 0.05, ** p < 0.01, *** p < 0.001. Data represent mean ± s.e.m. of 4 animals per group
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of non-cartilaginous airways, and in the submucosa (6.8-
fold, Fig. 3c) and adventitia (2.8-fold, Fig. 3d) of the car-
tilaginous airways, although the increase in the latter
was not significant. Airway eosinophilia was reduced
dose-dependently by both tiotropium (15–53 % inhib-
ition) and ciclesonide (2–62 % inhibition) treatment, and
this inhibitory effect was the most profound in the sub-
mucosa of cartilaginous airways (Fig. 3c).
Dose-finding in chronic asthma model - remodeling
To evaluate the effects of tiotropium and ciclesonide on
airway remodeling, airway smooth muscle mass was deter-
mined. In line with previous findings, repeated allergen
challenges induced airway smooth muscle thickening in
the non-cartilaginous airways (1.3-fold increase, Fig. 4a),
but not the cartilaginous airways (Fig. 4b). Airway smooth
muscle thickening was reduced by both tiotropium and
ciclesonide treatment, although in the small number of
animals used for the dose finding this was significant for
the animals treated with 0.1 mg/kg ciclesonide only
(100 % inhibition, Fig. 4a). In line with findings on airway
eosinophilia, the highest doses of tiotropium and cicleso-
nide appeared to be more effective (Fig. 4a). No remodel-
ing of the pulmonary microvasculature was observed. The
number of muscularized microvessels in the cartilaginous
airways was not changed in response to repeated allergen
challenges, nor was there any effect of tiotropium or cicle-
sonide treatment.
Drug combination in chronic asthma model –
inflammation
Based on the results of the dose-finding study in the
chronic asthma model, 0.01 mM tiotropium and
0.01 mg/kg ciclesonide were selected for the follow-up
study in which a combination of both drugs was investi-
gated. These doses were selected since in most cases
they produced only threshold effects on inflammation
and remodeling by themselves. In line with the dose-
finding study, ovalbumin challenge induced airway eosino-
philia in the submucosa (12.2-fold, Fig. 5a) and adventitia
(4.5-fold, Fig. 5b) of non-cartilaginous airways, and in the
submucosa (4.7-fold, Fig. 5i) and adventitia (3.1-fold,
Fig. 5j) of the cartilaginous airways. The combination of
tiotropium and ciclesonide had no effect on eosinophil
numbers in saline-challenged animals. Tiotropium
(0.01 mM) did not significantly affect eosinophil numbers
in the submucosa or adventitial compartments of both the
non-cartilaginous airways and the cartilaginous airways
(Fig. 5a, b, i and j). Similar effects were observed for
ciclesonide (0.01 mg/kg), which inhibited eosinophilia
in the submucosa of cartilaginous airways only (Fig. 5i).
Combined treatment with tiotropium and ciclesonide
had profound anti-inflammatory effects compared to
ovalbumin-challenged animals, inhibiting airway eo-
sinophilia by 74 to 80 % in all compartments (Fig. 5).
Drug interaction in chronic asthma model – remodeling
To assess the effect of the combination of tiotropium and
ciclesonide on airway remodeling, we analysed collagen
deposition and airway smooth muscle mass in response to
ovalbumin challenge. As described previously for this
model, no differences in airway collagen content in re-
sponse to allergen exposure were observed [22], and tio-
tropium or ciclesonide treatment had no effect on
collagen deposition either (data not shown). In line with
the results from the dose-finding study, ovalbumin chal-
lenge induced an increase in airway smooth muscle mass
in the non-cartilaginous airways compared to saline-
challenged animals (1.5-fold, Fig. 6), but had no effect on
smooth muscle mass in the cartilaginous airways (data not
shown). The combination of tiotropium and ciclesonide
had no effect on airway smooth muscle mass in saline-
Fig. 4 Airway smooth muscle mass thickening in response to chronic ovalbumin (OVA) challenge and treatment with saline (sal, control),
tiotropium (tio; 0.01 and 0.03 mM; nebulizer concentration) or ciclesonide (cicl; 0.01 and 0.1 mg/kg). Guinea pigs were treated as described in
Fig. 1b. Lungs were collected 24 h after the last OVA challenge and airway smooth muscle mass was determined by α-sm-myosin antibody
staining of non-cartilaginous (a) and cartilaginous airways (b). * p < 0.05. Data represent mean ± s.e.m. of 4 animals per group
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challenged animals. Tiotropium and ciclesonide alone did
not significantly inhibit ovalbumin-induced airway smooth
muscle mass, whereas the combination of tiotropium and
ciclesonide significantly inhibited ovalbumin-induced air-
way smooth muscle mass by 81 % (Fig. 6).
Discussion
The results of this study indicate that in vivo, tiotropium
and ciclesonide do not protect against acute allergen-
induced inflammation, but do protect against chronic
allergen-induced airway inflammation and remodeling.
Fig. 5 Airway eosinophilia in response to chronic ovalbumin (OVA) challenge and treatment with saline (sal; control), tiotropium (tio; 0.01 mM;
nebulizer concentration) and/or ciclesonide (cicl; 0.01 mg/kg). Guinea pigs were treated as described in Fig. 1b. Lungs were collected 24 h after
the last OVA challenge and eosinophil numbers were determined by H&E staining in the submucosa (a, i) and adventitia (b,j) of non-cartilaginous
(a,b) and cartilaginous (i,j) airways. Representative images are shown in panels c-h for non-cartilaginous airways (magnification 200x) and in
panels K-P for cartilaginous airways (maginification 100x). * p < 0.05, ** p < 0.01. Data represent mean ± s.e.m. of 8 animals per group
Fig. 6 Airway smooth muscle mass thickening in response to chronic ovalbumin (OVA) challenge and treatment with saline (sal; control),
tiotropium (tio; 0.01 mM; nebulizer concentration) and/or ciclesonide (cicl; 0.01 mg/kg). Guinea pigs were treated as described in Fig. 1b. Lungs
were collected 24 h after the last OVA challenge and airway smooth muscle mass was determined by α-sm-myosin antibody staining. Quantification is
shown in figure a for non-cartilaginous airways and representative images are shown in panels b-g (magnification 200x). * p < 0.05. Data represent
mean ± s.e.m. of 8 animals per group
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Whereas there was only limited inhibition of airway eo-
sinophilia and airway smooth muscle thickening after
treatment with the monotherapies at threshold doses,
allergen-induced alterations were significantly inhibited
by pretreatment with the combination of both com-
pounds. This suggests that combination therapy with
tiotropium and ciclesonide might have beneficial effects
on airway inflammation and remodeling. The potential
for a steroid-sparing effect needs additional studies.
To our knowledge, this is the first study demonstrating
functional interactions of anticholinergics and cortico-
steroids on inflammation and remodeling in vivo. Previ-
ously, it has been shown in mice and guinea pigs that
monotherapy with higher doses of tiotropium or cortico-
steroids can inhibit allergen-induced inflammation and
remodeling [21, 22, 25]. Tiotropium and dexamethasone
alone, both at a dose of 1 mg/kg, inhibit airway inflam-
mation in response to ovalbumin in mice [25]. Using the
chronic guinea pig model as described in this study, we
reported inhibitory effects of tiotropium and budesonide
on inflammation and remodeling at 0.1 mM [21, 22].
The effects observed on airway eosinophilia in the latter
study were comparable to the effects observed with the
highest dose in the current study (0.03 mM tiotropium
and 0.1 mg/kg ciclesonide), suggesting that the inhibi-
tory effects occur at much lower doses than previously
thought, and that approximately 50 % inhibition of
airway eosinophilia by these treatments is the maximal
effect that can be achieved with anticholinergic or cor-
ticosteroid treatment in this model. In this study, we
demonstrate that tiotropium and ciclesonide at even
lower doses of 0.01 mM and 0.01 mg/kg respectively,
significantly inhibit airway inflammation and remodeling
when administered in combination, with no effect on
inflammation or remodeling by the monotherapies at
these doses.
Synergistic effects between anticholinergics and cortico-
steroids have also been observed in vitro. It has been
shown that glycopyrrolate alone does not affect TNF-
alpha release from monocytes, but synergistically en-
hances the inhibitory effects of budesonide on TNF-alpha
release [23]. This synergy between anticholinergics and
corticosteroids on inflammatory processes is now con-
firmed by our in vivo findings. Randomized clinical trials
investigating the effects of long-acting anticholinergics in
asthma have only recently attracted attention, and there is
no study that has investigated synergism between anticho-
linergics and corticosteroids in patients with asthma.
However, beneficial effects of combining anticholinergics
and corticosteroids have been reported. The addition of
tiotropium to treatment for patients with uncontrolled
asthma was shown to be more effective on improving
asthma symptoms and lung function than doubling the
dose of corticosteroids [26]. Improvements in morning
peak expiratory flow, the proportion of asthma-control
days, forced expiratory volume in 1 s and daily symptom
scores were reported in this crossover trial [26]. Further-
more, randomized controlled clinical trials demonstrated
that treatment with tiotropium, added on to ICS or ICS
plus LABA, is an effective therapy for moderate and se-
vere asthma patients as seen by improvements in lung
function and reduction in the risk of severe asthma exac-
erbations [5–7], indicating at least additive effects of tio-
tropium when added to ICS +/− LABA treatment.
The mechanistic basis for functional interactions be-
tween anticholinergics and corticosteroids is not yet clear,
but it may well be that these drugs target specific and
distinct pathophysiological processes. Ciclesonide, via
glucocorticosteroid receptors, acts anti-inflammatory by
repressing pro-inflammatory gene transcription [27].
These mechanisms are most likely different from those
targeted by tiotropium, which acts via G-protein
coupled muscarinic receptors. In vitro evidence exists
for anti-inflammatory and anti-remodeling effects of
anticholinergics on airway cells via muscarinic recep-
tors [8]. Anticholinergics inhibit the release of neutro-
phil chemotactic mediators from a number of cells,
including macrophages, fibroblasts, airway smooth
muscle cells and epithelial cells [11-13]. Anticholiner-
gics also inhibit parameters of remodeling, including
enhanced MUC5AC expression, goblet cell metaplasia,
and fibroblast to myofibroblast transition [16, 28, 29].
In addition, bronchoconstriction is effectively targeted
by tiotropium, and this may also have its effects on airway
inflammation and remodeling [30, 31]. This hypothesis is
supported by recent data showing that repeated metha-
choline challenges induce remodeling in mild asthma pa-
tients [32]. Moreover, we demonstrated that muscarinic
M3 receptor knock-out mice are protected from allergen-
induced airway remodeling, even though there is still an
inflammatory response in these animals [20]. Because M3
receptors mediate bronchoconstriction, which is abolished
in M3 receptor knock-out mice [33], this may suggest that
bronchoconstriction by itself might be an important driver
of airway remodeling [20, 31]. In support, we previously
demonstrated that methacholine treatment promotes re-
modeling in guinea pig lung slices [34]. Taken together,
we propose that additive effects between anticholinergics
and corticosteroids, as observed for tiotropium and cicle-
sonide in our study, are based on the different mecha-
nisms they target.
Surprisingly, no anti-inflammatory effects of tiotro-
pium and ciclesonide were observed in the acute asthma
model in this study. Similar findings were observed for
tiotropium and the long-acting β-agonist olodaterol in
an acute guinea pig model [35]. Apparently, chronic
treatment is needed to unmask the anti-inflammatory
effects in guinea pigs, as we do observe inhibition of
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inflammation in this study and previous studies after
multiple allergen challenges [22]. Because mast cell infil-
tration occurs already after the systemic sensitization
against ovalbumin (i.e. prior to the first drug treatment),
it may be that tiotropium cannot protect against the ini-
tial inflammatory response induced by the first allergen
encounter, but requires prolonged treatment. In support,
anticholinergics do not inhibit mast cell degranulation
[36]. Similarly, the effects of corticosteroids require
prolonged treatment, as the same discrepancy between
acute and chronic inflammation was seen for ciclesonide,
which was substantially more effective, and at lower doses
already, in inhibiting chronic allergen-induced inflamma-
tion compared with acute allergen-induced inflammation.
Limitations in the delivery of the drugs do not explain the
difference, as a single administration of tiotropium effect-
ively prevents bronchoconstriction and the early and late
asthmatic reaction [35], and a single administration of cor-
ticosteroids inhibits the late asthmatic reaction in this
model (unpublished observations). The mechanistic basis
for the delay in the onset of action of tiotropium is un-
clear, however, it can be envisaged that the role of acetyl-
choline is further downstream in the pathophysiological
process. This is supported by the fact that sensory nerves
play an important role in the late asthmatic reaction, and
not in the early asthmatic reaction [37]. It may therefore
be that an initial inflammatory response is required,
which leads to epithelial damage, inflammatory medi-
ator release and other mechanisms that enhance the
cholinergic reflex, and thereby increase the role of
acetylcholine later on.
The finding that tiotropium and ciclesonide protect
against allergen-induced airway smooth muscle thickening
is in agreement with our previous findings [21]. The re-
duction in smooth muscle mass may be related to the re-
duction in airway inflammation, as many inflammatory
mediators are reported to promote smooth muscle growth
in allergic airway inflammation [38]. Alternatively, in-
creased cholinergic activity that results from airway in-
flammation promotes bronchoconstriction, which might
drive airway remodeling as discussed above.
Conclusion
In conclusion, chronic treatment with a combination of
low dose tiotropium and ciclesonide inhibits airway in-
flammation and remodeling in a guinea pig model of
chronic asthma, suggesting that treatment with tiotropium
and ciclesonide may have anti-inflammatory and anti-
remodeling activity in allergic airway diseases. Given the
fact that tiotropium is now registered as a therapy for
asthma added on to ICS and LABA treatment, beneficial
effects of combination therapy on these inflammatory and
remodeling parameters may be clinically relevant.
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